UK NEQAS for Leucocyte Immunophenotyping

CD34 Stem Cell Programme

Sample - 208

All Participant Report

Distribution - 141505

Participant ID - 42981

Date Issued - 16 February 2015

Closing Date - 06 March 2015

Machine Used -

Trial Comments

The CD34 trial 141505 was issued to 313 participants for flow cytometric enumeration of CD34+ stem cells.

Sample Comments

The sample was manufactured by UK NEQAS using stabilised CD34+ samples and stabilised leucodepleted blood

Absolute Values Results and Performance

Please note: Performance monitoring for this programme is on absolute values only. Percentage results are shown for information purposes only.

Cell Population	Your Results (cells/µL)	Robust Mean (cells/µL)	Robust SD (cells/µL)
CD34 Absolute Values		25.73	3.29

Cell Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
CD34 Absolute Values		Action	0	1	0

Percentage Values Results and Performance

Cell Population	Your Results %	Robust Mean %	Robust SD %
CD34 Percentage Values		0.33	0.04

Cell Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
CD34 Percentage Values		Action	0	1	0

***z Score Limits Definitions**

Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is <u>not</u> applicable to the Cusum control charts.

UK NEQAS for Leucocyte Immunophenotyping

CD34 Stem Cell Programme

Sample - 208

Histograms of Participant z Scores

Absolute Values (cells/µL)

Please note ▼ denotes your result



Percentage Values (%)

Please note ▼ denotes your result



UK NEQAS for Leucocyte Immunophenotyping

CD34 Stem Cell Programme

Sample - 208

Shewhart Control Charts

(Please note each data point represents a single sample)

Absolute Values (cells/µL)



Percentage Values (%)



Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Absolute Values (cells/µL)



Percentage Values (%)



UKNEQAS for Leucocyte Immunophenotyping

CD34 Stem Cell Programme

Sample - 208

Platform Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
FLOW COUNT	83	26.73	3.08	83	0.33	0.05
HAEMATOLOGY ANALYSER WBC	31	24.66	3.70	31	0.31	0.04
TRUCOUNT	139	25.27	3.31	132	0.33	0.04

Lysing Method Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
Ammonium Chloride (NH4CL)	113	25.83	3.30	110	0.33	0.04
Facslyse	22	24.18	3.59	21	0.30	0.04
Pharmlyse	51	25.13	3.70	47	0.32	0.04
Stem Kit Lyse	53	25.60	3.33	53	0.32	0.05

Antibody Fluorochrome Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
PE	271	25.46	3.66	263	0.32	0.05

Flow Cytometer Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
Facscalibur	47	25.23	3.45	44	0.32	0.04
Facscanto	23	23.67	4.47	22	0.31	0.05
Facscanto II	96	25.48	3.10	92	0.33	0.03
FC 500.	55	26.56	2.96	55	0.32	0.05
Navios	41	25.44	3.34	41	0.32	0.06

Gating Strategy Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
BD STEM CELL ENUMERATION KIT	44	25.07	2.41	43	0.33	0.03
ISHAGE	193	25.58	3.94	186	0.32	0.05
STEM KIT	35	25.60	3.16	35	0.32	0.05

UK NEQAS for Leucocyte Immunophenotyping

CD34 Stem Cell Programme

Sample - 209

Distribution - 141505

Participant ID - 42981

Date Issued - 16 February 2015

Closing Date - 06 March 2015

Machine Used -

Trial Comments

The CD34 trial 141505 was issued to 313 participants for flow cytometric enumeration of CD34+ stem cells.

Sample Comments

The sample was manufactured by UK NEQAS using stabilised CD34+ samples and stabilised leucodepleted blood

Absolute Values Results and Performance

Please note: Performance monitoring for this programme is on absolute values only. Percentage results are shown for information purposes only.

Cell Population	Your Results (cells/µL)	Robust Mean (cells/µL)	Robust SD (cells/µL)
CD34 Absolute Values		27.50	3.11

Cell Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
CD34 Absolute Values		Action	0	2	0

Percentage Values Results and Performance

Cell Population	Your Results %	Robust Mean %	Robust SD %
CD34 Percentage Values		0.24	0.03

Cell Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
CD34 Percentage Values		Action	0	2	0

***z Score Limits Definitions**

Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts.



Histograms of Participant z Scores

Absolute Values (cells/µL)

Please note ▼ denotes your result



Percentage Values (%)

Please note ▼ denotes your result



Shewhart Control Charts

(Please note each data point represents a single sample)

Absolute Values (cells/µL)



Percentage Values (%)



UKNEQAS for Leucocyte Immunophenotyping

CD34 Stem Cell Programme

Sample - 209

Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Absolute Values (cells/µL)



Percentage Values (%)



UKNEQAS for Leucocyte Immunophenotyping

CD34 Stem Cell Programme

Sample - 209

Platform Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
FLOW COUNT	83	28.23	2.85	83	0.24	0.03
HAEMATOLOGY ANALYSER WBC	31	27.23	3.37	31	0.23	0.03
TRUCOUNT	139	27.04	3.10	132	0.23	0.03

Lysing Method Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
Ammonium Chloride (NH4CL)	113	27.64	2.92	110	0.23	0.03
Facslyse	22	28.18	3.04	21	0.24	0.02
Pharmlyse	51	26.91	3.34	47	0.23	0.03
Stem Kit Lyse	53	27.29	3.16	53	0.24	0.03

Antibody Fluorochrome Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
PE	270	27.47	3.14	262	0.24	0.03

Flow Cytometer Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
Facscalibur	47	27.16	2.92	44	0.23	0.03
Facscanto	23	26.73	3.13	22	0.24	0.03
Facscanto II	96	27.68	3.25	92	0.24	0.02
FC 500.	55	27.87	3.11	55	0.23	0.03
Navios	41	27.33	3.09	41	0.23	0.03

Gating Strategy Specific Statistics

(Please note only groups of >20 returns are displayed)

Method	Absolute Count Values (cells/µL)			Percentage Values		
	Returns	Robust Mean	Robust SD	Returns	Robust Mean	Robust SD
BD STEM CELL ENUMERATION KIT	44	26.99	2.47	43	0.24	0.02
ISHAGE	193	27.49	3.35	186	0.23	0.03
STEM KIT	35	27.78	2.88	35	0.24	0.03

Information with respect to compliance with standards BS EN ISO/IEC 17043:2010

4.8.2 a) The proficiency testing provider for this programme is:
UK NEQAS for Leucocyte Immunophenotyping
Pegasus House, 4th Floor Suite
463A Glossop Road
Sheffield, S10 2QD
United Kingdom
Tel: +44 (0) 114 267 3600, Fax: +44 (0) 114 267 3601
e-mail: nicola.rose@ukneqasli.co.uk

4.8.2 b) The coordinators of UK NEQAS LI programmes are Prof David Barnett and Mr Liam Whitby.

4.8.2 c) Person(s) authorizing this report:
Prof David Barnett, Director or Mr Liam Whitby, Operations Manager of UK NEQAS LI

4.8.2 d) No activities in relation to this EQA exercise were subcontracted.

4.8.2 g) The UK NEQAS LI Confidentiality Policy can be found in the Quality Manual which is available by contacting the UK NEQAS LI office. Participant details, their results and their performance data remain confidential unless revealed to the relevant NQAAP when a UK participant is identified as having performance issues.

4.8.2 i) All EQA samples are prepared in accordance with strict Standard Operational Procedures by trained personnel proven to ensure homogeneity and stability. Where appropriate/possible EQA samples are tested prior to issue. Where the sample(s) issued is stabilised blood or platelets, pre and post stability testing will have proved sample suitability prior to issue.

4.8.2 l), n), o), r) & s) Please refer to the UK NEQAS LI website at www.ukneqasli.co.uk for detailed information on each programme including the scoring systems applied to assess performance. Where a scoring system refers to the 'consensus result' this means the result reported by the majority of participants for that trial issue. Advice on the interpretation of statistical analyses and the criteria on which performance is measured is also given. Please note that where different methods/procedures are used by different groups of participants these may be displayed within your report, but the same scoring system is applied to all participants irrespective of method/procedure used.

4.8.2 m) We do not assign values against reference materials or calibrants.

4.8.2 q) Details of the programme designs as authorized by The Steering Committee and Specialist Advisory Group can be found on our website at www.ukneqasli.co.uk. The proposed trial issue schedule for each programme is also available.

4.8.2 t) If you would like to discuss the outcomes of this trial issue, please contact UK NEQAS LI using the contact details provided.